Which angiotensin‑converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) has the lowest risk of hyperkalemia in elderly patients?

No Single ACEI or ARB Has Definitively Lower Hyperkalemia Risk in the Elderly

The available evidence does not identify a specific ACEI or ARB with consistently lower hyperkalemia risk in elderly patients—all agents in both classes carry similar risk, and the focus should be on dose optimization and monitoring rather than agent selection. 1

Key Evidence on Class Comparison

ACEIs vs ARBs: Hyperkalemia Risk Profile

The most relevant research directly comparing these classes shows:

• ARBs may actually carry higher hyperkalemia risk than ACEIs in some populations. A large retrospective study of over 2,300 veterans found hyperkalemia (>5 mEq/L) occurred in 31.0% of ARB users versus 20.4% of ACEI users, with severe hyperkalemia (≥6 mEq/L) in 2.8% versus 0.8% respectively 2. ARB use was associated with 42-56% increased odds of hyperkalemia compared to ACEIs after adjusting for renal function.

• Real-world post-marketing surveillance data from 11,301 adverse events confirmed hyperkalemia was reported more frequently with ACEIs (28.70%) than ARBs (14.14%), though ARBs showed more AKI 3. However, this contradicts the controlled study above, highlighting inconsistency in the literature.

• The combination of ACEI + ARB dramatically increases risk and should be avoided—this combination showed the highest reporting ratios for both hyperkalemia and AKI across all algorithms 3.

Guideline Perspective: No Preferred Agent

Multiple authoritative guidelines explicitly state no preference exists:

• The 2003 American Geriatrics Society guidelines note that "one specific medication for managing blood pressure in older adults with DM is not recommended" but emphasize that moderate-dose ACEIs (captopril 75 mg/d, enalapril 10 mg/d, or lisinopril 10 mg/d) are significantly associated with hyperkalemia development 1.

• The 2007 ESC/ESH guidelines conclude there are "insufficient grounds for an age-depending strategy in the choice of antihypertensive agents" among ACEIs, ARBs, and other classes 4.

• The 2022 ESC cardiovascular pharmacotherapy review identifies mineralocorticoid receptor antagonists as the highest hyperkalemia risk (especially with creatinine clearance <30 mL/min, doses >25 mg daily, or concurrent ACEI/ARB use), but does not differentiate between ACEI and ARB risk 5.

Critical Management Strategy

Dose Matters More Than Agent Selection

Start low and titrate gradually in elderly patients 4. The guidelines consistently emphasize:

• Initial doses and titration should be more gradual in elderly patients due to greater chance of adverse effects, especially in very old and frail subjects 4
• Lower doses may reduce hyperkalemia risk while maintaining cardiovascular benefit
• The 2001 ESC heart failure guidelines specifically note elderly patients may be more susceptible to adverse effects and recommend low-dose titration with prolonged periods 6

Mandatory Monitoring Protocol

Monitor renal function and serum potassium within 1-2 weeks of initiation, with each dose increase, and at least yearly 1. This is a Grade IIIA recommendation from the American Geriatrics Society.

The 2022 ESC expert consensus provides specific thresholds 5:

• K+ 4.5-5.0 mEq/L: Initiate/up-titrate RAASi with close monitoring; start potassium-lowering therapy if K+ increases >5.0
• K+ >5.0-6.5 mEq/L: If at maximum tolerated dose, initiate potassium-lowering therapy; if not, start RAASi when K+ <5.0
• K+ >6.5 mEq/L: Discontinue or reduce RAASi therapy

Risk Factors Requiring Extra Caution

Elderly patients with these characteristics face highest hyperkalemia risk:

• Chronic kidney disease (especially CrCl <30 mL/min) 5, 6
• Diabetes mellitus 1, 2
• Concurrent potassium-sparing diuretics (amiloride, triamterene, spironolactone >25 mg) 5, 6
• Age >85 years showed higher rates of both ARF (HR 1.15) and hyperkalemia (HR 1.33) after MI 7
• Dehydration, reduced GFR, or metabolic acidosis 6

Common Pitfalls to Avoid

1. Don't combine ACEI + ARB—this substantially increases hyperkalemia and AKI risk without additional cardiovascular benefit 3

2. Don't assume ARBs are safer—despite lower cough/angioedema rates, hyperkalemia risk appears similar or potentially higher 2, 3

3. Don't discontinue prematurely—a single mild elevation in potassium (5.0-5.5 mEq/L) doesn't require stopping therapy; address contributing factors first and continue monitoring 8

4. Don't neglect standing blood pressure—elderly patients have increased postural hypotension risk, requiring both supine and standing measurements 4

5. Don't use potassium supplements concurrently without very close monitoring—this dramatically increases hyperkalemia risk 5

Practical Algorithm

1. Select any ACEI or ARB based on cost, formulary, and patient comorbidities (no agent has proven lower hyperkalemia risk)
2. Start at ≤50% of target dose in elderly patients
3. Check K+ and creatinine within 1-2 weeks
4. If K+ <5.0 mEq/L: Continue titration toward guideline-recommended doses
5. If K+ 5.0-5.5 mEq/L: Hold dose escalation, address contributing factors (dehydration, NSAIDs, other drugs), recheck in 1 week
6. If K+ 5.6-6.5 mEq/L: Consider dose reduction or potassium binder; don't automatically discontinue
7. If K+ >6.5 mEq/L: Discontinue temporarily, treat hyperkalemia, restart at lower dose when K+ <5.0 mEq/L

The evidence strongly supports that monitoring strategy and dose optimization matter far more than which specific ACEI or ARB you choose in elderly patients.